1.29%
13.65%
-21.79%
-27.49%
170.24%
98.86%
15.96%
AI Spotlight on RNA
Company Description
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies.It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases.The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage.
It also offers Lumizyme therapy for Pompe diseases.Avidity Biosciences, Inc.was incorporated in 2012 and is headquartered in San Diego, California.
Market Data
| Last Price | 33.05 |
| Change Percentage | 1.29% |
| Open | 32.75 |
| Previous Close | 32.63 |
| Market Cap ( Millions) | 3943 |
| Volume | 358784 |
| Year High | 56 |
| Year Low | 11.23 |
| M A 50 | 34.61 |
| M A 200 | 37.84 |
Financial Ratios
| FCF Yield | -4.78% |
| Dividend Yield | 0.00% |
| ROE | -27.66% |
| Debt / Equity | 0.51% |
| Net Debt / EBIDTA | 112.35% |
| Price To Book | 2.71 |
| Price Earnings Ratio | -14.54 |
| Price To FCF | -20.92 |
| Price To sales | 389.76 |
| EV / EBITDA | -11.09 |
News
- Jan -20 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan -08 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jan -08 - Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025
- Dec -20 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dec -11 - Avidity Biosciences Advances With FDA Clearance And Promising Data For Rare Diseases
- Nov -26 - Avidity Biosciences to Participate in Upcoming Investor Conference
- Nov -21 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Nov -14 - RNA Stock Hits Record High on Entering the Cardiac Disease Space
- Nov -13 - Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News
- Nov -12 - Avidity Biosciences Announces New Precision Cardiology Development Candidates to Treat Rare Genetic Cardiomyopathies and Provides First Look at Next-Generation Technology Innovations
- Nov -08 - Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Lags Revenue Estimates
- Nov -07 - Avidity Biosciences Reports Third Quarter 2024 Financial Results and Recent Highlights
- Nov -06 - Analysts Estimate Avidity Biosciences, Inc. (RNA) to Report a Decline in Earnings: What to Look Out for
- Oct -31 - Avidity Biosciences to Host Investor and Analyst Event Focused on Precision Cardiology Candidates and First Look at Next-Generation Technology Innovations on November 12, 2024
- Oct -21 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Oct -04 - Why Avidity Biosciences Zoomed to a 12% Gain This Week
- Sep -25 - Avidity Biosciences to Participate in Upcoming Investor Conference
- Sep -24 - Goldman Sachs Bullish On Avidity Biosciences, Cites Scalable RNA Therapeutics Platform For Rare Diseases
- Sep -23 - Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sep -08 - 3 Crazy Stocks to Buy That Are Outperforming Nvidia in 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Antibody Oligonucleotide Conjugates
Expected Growth : 12.05 %
What the company do ?
Antibody Oligonucleotide Conjugates from Avidity Biosciences, Inc. are novel therapeutic molecules that combine the targeting ability of antibodies with the specificity of oligonucleotides to modulate gene expression.
Why we expect these perspectives ?
Avidity Biosciences' Antibody Oligonucleotide Conjugates' 12.05% growth is driven by increasing adoption in targeted therapies, rising demand for precision medicine, and advancements in RNA-based treatments. Strong partnerships, expanding pipeline, and growing investments in gene therapy research also contribute to this growth.
Avidity Biosciences, Inc. Products
| Product Range | What is it ? |
|---|---|
| AOC 1001 | AOC 1001 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases. |
| AOC 1020 | AOC 1020 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases. |
| AOC 1044 | AOC 1044 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases. |
| AOC 1067 | AOC 1067 is a phosphorothioate oligonucleotide that selectively targets and inhibits the expression of a specific gene, which is associated with various diseases. |
Avidity Biosciences, Inc.'s Porter Forces
Threat Of Substitutes
Avidity Biosciences, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Avidity Biosciences, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are highly specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Avidity Biosciences, Inc. relies on a few key suppliers for raw materials and equipment. While the company has some bargaining power due to its size and reputation, the suppliers still have some leverage due to the specialized nature of the products.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant capital requirements, complex regulatory frameworks, and the need for specialized expertise. These barriers make it difficult for new entrants to compete with established companies like Avidity Biosciences, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established companies competing for market share. Avidity Biosciences, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 1.93% |
| Debt Cost | 3.95% |
| Equity Weight | 98.07% |
| Equity Cost | 7.87% |
| WACC | 7.80% |
| Leverage | 1.97% |
Avidity Biosciences, Inc. : Quality Control
Avidity Biosciences, Inc. passed 3 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CRNX | Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, … |
| SRPT | Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It … |
| BPMC | Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment … |
| AGIO | Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) … |
| SWTX | SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Agios Pharmaceuticals
A-Score
1-Year Total Return ->
🥈
Avidity Biosciences
A-Score
1-Year Total Return ->
🥉
Crinetics Pharmaceuticals
A-Score
1-Year Total Return ->
4
Blueprint Medicines
A-Score
1-Year Total Return ->
5
Sarepta Therapeutics
A-Score
1-Year Total Return ->
6
